Skip to main content
Erschienen in: International Journal of Colorectal Disease 2/2017

20.10.2016 | Original Article

Combining aneuploidy and dysplasia for colitis’ cancer risk assessment outperforms current surveillance efficiency: a meta-analysis

verfasst von: Rüdiger Meyer, Sandra Freitag-Wolf, Silke Blindow, Jürgen Büning, Jens K. Habermann

Erschienen in: International Journal of Colorectal Disease | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cancer risk assessment for ulcerative colitis patients by evaluating histological changes through colonoscopy surveillance is still challenging. Thus, additional parameters of high prognostic impact for the development of colitis-associated carcinoma are necessary. This meta-analysis was conducted to clarify the value of aneuploidy as predictor for individual cancer risk compared with current surveillance parameters.

Methods

A systematic web-based search identified studies published in English that addressed the relevance of the ploidy status for individual cancer risk during surveillance in comparison to neoplastic mucosal changes. The resulting data were included into a meta-analysis, and odds ratios (OR) were calculated for aneuploidy or dysplasia or aneuploidy plus dysplasia.

Results

Twelve studies addressing the relevance of aneuploidy compared to dyplasia were comprehensively evaluated and further used for meta-analysis. The meta-analysis revealed that aneuploidy (OR 5.31 [95 % CI 2.03, 13.93]) is an equally effective parameter for cancer risk assessment in ulcerative colitis patients as dysplasia (OR 4.93 [1.61, 15.11]). Strikingly, the combined assessment of dysplasia and aneuploidy is superior compared to applying each parameter alone (OR 8.99 [3.08, 26.26]).

Conclusions

This meta-analysis reveals that aneuploidy is an equally effective parameter for individual cancer risk assessment in ulcerative colitis as the detection of dysplasia. More important, the combined assessment of dysplasia and aneuploidy outperforms the use of each parameter alone. We suggest image cytometry for ploidy assessment to become an additional feature of consensus criteria to individually assess cancer risk in UC.
Literatur
1.
Zurück zum Zitat Crohn UB, Rosenberg H (1925) The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci 170:220–228CrossRef Crohn UB, Rosenberg H (1925) The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci 170:220–228CrossRef
2.
Zurück zum Zitat Campbell S, Ghosh S (2002) Ulcerative colitis and colon cancer: strategies for cancer prevention. Dig Dis 20(1):38–48 doi: ddi20038 [pii]PubMedCrossRef Campbell S, Ghosh S (2002) Ulcerative colitis and colon cancer: strategies for cancer prevention. Dig Dis 20(1):38–48 doi: ddi20038 [pii]PubMedCrossRef
4.
Zurück zum Zitat Winther KV, Jess T, Langholz E, Munkholm P, Binder V (2004) Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2(12):1088–1095CrossRef Winther KV, Jess T, Langholz E, Munkholm P, Binder V (2004) Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 2(12):1088–1095CrossRef
5.
Zurück zum Zitat Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B (2013) Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 19(4):789–799. doi:10.1097/MIB.0b013e31828029c0 PubMedCrossRef Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B (2013) Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 19(4):789–799. doi:10.​1097/​MIB.​0b013e31828029c0​ PubMedCrossRef
6.
8.
Zurück zum Zitat Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC et al (1983) Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14(11):931–968PubMedCrossRef Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC et al (1983) Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14(11):931–968PubMedCrossRef
9.
Zurück zum Zitat Seril DN, Liao J, Yang GY, Yang CS (2003) Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 24(3):353–362PubMedCrossRef Seril DN, Liao J, Yang GY, Yang CS (2003) Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 24(3):353–362PubMedCrossRef
10.
Zurück zum Zitat Terzic J, Grivennikov S, Karin E, Karin M (2010) Inflammation and colon cancer. Gastroenterology 138(6):2101–2114 e 2105. doi: S0016-5085(10)00176-9 [pii] 053/j.gastro.2010.01.058PubMedCrossRef Terzic J, Grivennikov S, Karin E, Karin M (2010) Inflammation and colon cancer. Gastroenterology 138(6):2101–2114 e 2105. doi: S0016-5085(10)00176-9 [pii] 053/j.gastro.2010.01.058PubMedCrossRef
11.
Zurück zum Zitat Stange EF, Travis SP (2008) The European consensus on ulcerative colitis: new horizons? Gut 57(8):1029–1031 doi: gut.2007.146761 [pii] 1136/gut.2007.146761PubMedCrossRef Stange EF, Travis SP (2008) The European consensus on ulcerative colitis: new horizons? Gut 57(8):1029–1031 doi: gut.2007.146761 [pii] 1136/gut.2007.146761PubMedCrossRef
12.
Zurück zum Zitat Itzkowitz SH, Present DH (2005) Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11(3):314–321 doi: 00054725-200503000-00012 [pii]PubMedCrossRef Itzkowitz SH, Present DH (2005) Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis 11(3):314–321 doi: 00054725-200503000-00012 [pii]PubMedCrossRef
14.
Zurück zum Zitat Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124(2):544–560. doi:10.1053/gast.2003.50044 S0016508502158951 [pii]PubMedCrossRef Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, Litin S, Simmang C (2003) Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124(2):544–560. doi:10.​1053/​gast.​2003.​50044 S0016508502158951 [pii]PubMedCrossRef
16.
Zurück zum Zitat Rubin DT, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB (2007) Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc 65(7):998–1004 doi: S0016-5107(06)02950-6 [pii] 1016/j.gie.2006.09.025PubMedCrossRef Rubin DT, Rothe JA, Hetzel JT, Cohen RD, Hanauer SB (2007) Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis? Gastrointest Endosc 65(7):998–1004 doi: S0016-5107(06)02950-6 [pii] 1016/j.gie.2006.09.025PubMedCrossRef
17.
Zurück zum Zitat Lutgens MW, Vleggaar FP, Schipper ME, Stokkers PC, van der Woude CJ, Hommes DW, de Jong DJ, Dijkstra G, van Bodegraven AA, Oldenburg B, Samsom M (2008) High frequency of early colorectal cancer in inflammatory bowel disease. Gut 57(9):1246–1251 doi: gut.2007.143453 [pii] 1136/gut.2007.143453PubMedCrossRef Lutgens MW, Vleggaar FP, Schipper ME, Stokkers PC, van der Woude CJ, Hommes DW, de Jong DJ, Dijkstra G, van Bodegraven AA, Oldenburg B, Samsom M (2008) High frequency of early colorectal cancer in inflammatory bowel disease. Gut 57(9):1246–1251 doi: gut.2007.143453 [pii] 1136/gut.2007.143453PubMedCrossRef
18.
Zurück zum Zitat Meyer R, Laubert T, Sommer M, Benecke C, Lehnert H, Fellermann K, Bruch HP, Keck T, Thorns C, Habermann JK, Buning J (2015) Colorectal neoplasia in IBD-a single-center analysis of patients undergoing proctocolectomy. Int J Color Dis 30(6):821–829. doi:10.1007/s00384-015-2217-7 CrossRef Meyer R, Laubert T, Sommer M, Benecke C, Lehnert H, Fellermann K, Bruch HP, Keck T, Thorns C, Habermann JK, Buning J (2015) Colorectal neoplasia in IBD-a single-center analysis of patients undergoing proctocolectomy. Int J Color Dis 30(6):821–829. doi:10.​1007/​s00384-015-2217-7 CrossRef
19.
Zurück zum Zitat Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH (1994) Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 107(4):934–944 doi: S0016508594003082 [pii]PubMedCrossRef Connell WR, Lennard-Jones JE, Williams CB, Talbot IC, Price AB, Wilkinson KH (1994) Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 107(4):934–944 doi: S0016508594003082 [pii]PubMedCrossRef
20.
21.
Zurück zum Zitat Riddell RH (1998) How reliable/valid is dysplasia in identifying at-risk patients with ulcerative colitis? J Gastrointest Surg 2(4):314–317 doi: S1091-255X(98)80068-1 [pii]PubMedCrossRef Riddell RH (1998) How reliable/valid is dysplasia in identifying at-risk patients with ulcerative colitis? J Gastrointest Surg 2(4):314–317 doi: S1091-255X(98)80068-1 [pii]PubMedCrossRef
22.
Zurück zum Zitat Dobbins WO 3rd (1977) Current status of the precancer lesion in ulcerative colitis. Gastroenterology 73(6):1431–1433PubMed Dobbins WO 3rd (1977) Current status of the precancer lesion in ulcerative colitis. Gastroenterology 73(6):1431–1433PubMed
23.
Zurück zum Zitat Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, Rabinovitch PS (1992) DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103(5):1611–1620PubMedCrossRef Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, Rabinovitch PS (1992) DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103(5):1611–1620PubMedCrossRef
24.
Zurück zum Zitat Collins PD, Mpofu C, Watson AJ, Rhodes JM (2006) Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2:CD000279. doi:10.1002/14651858.CD000279.pub3 Collins PD, Mpofu C, Watson AJ, Rhodes JM (2006) Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2:CD000279. doi:10.​1002/​14651858.​CD000279.​pub3
25.
Zurück zum Zitat Bernstein CN, Weinstein WM, Levine DS, Shanahan F (1995) Physicians’ perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol 90(12):2106–2114PubMed Bernstein CN, Weinstein WM, Levine DS, Shanahan F (1995) Physicians’ perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol 90(12):2106–2114PubMed
26.
Zurück zum Zitat Eaden JA, Ward BA, Mayberry JF (2000) How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc 51(2):123–128 doi: S0016510700310124 [pii]PubMedCrossRef Eaden JA, Ward BA, Mayberry JF (2000) How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance. Gastrointest Endosc 51(2):123–128 doi: S0016510700310124 [pii]PubMedCrossRef
27.
Zurück zum Zitat Dixon MF, Brown LJ, Gilmour HM, Price AB, Smeeton NC, Talbot IC, Williams GT (1988) Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology 13(4):385–397PubMedCrossRef Dixon MF, Brown LJ, Gilmour HM, Price AB, Smeeton NC, Talbot IC, Williams GT (1988) Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology 13(4):385–397PubMedCrossRef
28.
Zurück zum Zitat Odze RD, Tomaszewski JE, Furth EE, Feldman MD, Diallo R, Poremba C, Becker I, Hoefler H, Goldblum JR, Rybicki LA, Alsaigh N, Fogt F (2006) Variability in the diagnosis of dysplasia in ulcerative colitis by dynamic telepathology. Oncol Rep 16(5):1123–1129PubMed Odze RD, Tomaszewski JE, Furth EE, Feldman MD, Diallo R, Poremba C, Becker I, Hoefler H, Goldblum JR, Rybicki LA, Alsaigh N, Fogt F (2006) Variability in the diagnosis of dysplasia in ulcerative colitis by dynamic telepathology. Oncol Rep 16(5):1123–1129PubMed
29.
Zurück zum Zitat Melville DM, Jass JR, Shepherd NA, Northover JM, Capellaro D, Richman PI, Lennard-Jones JE, Ritchie JK, Andersen SN (1988) Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations. Gastroenterology 95(3):668–675 doi:S001650858800280X [pii]PubMedCrossRef Melville DM, Jass JR, Shepherd NA, Northover JM, Capellaro D, Richman PI, Lennard-Jones JE, Ritchie JK, Andersen SN (1988) Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations. Gastroenterology 95(3):668–675 doi:S001650858800280X [pii]PubMedCrossRef
30.
Zurück zum Zitat Eaden J, Abrams K, McKay H, Denley H, Mayberry J (2001) Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol 194(2):152–157. doi:10.1002/path.876 [pii] 1002/path.876PubMedCrossRef Eaden J, Abrams K, McKay H, Denley H, Mayberry J (2001) Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol 194(2):152–157. doi:10.​1002/​path.​876 [pii] 1002/path.876PubMedCrossRef
31.
Zurück zum Zitat Dundas SA, Kay R, Beck S, Cotton DW, Coup AJ, Slater DN, Underwood JC (1987) Can histopathologists reliably assess dysplasia in chronic inflammatory bowel disease? J Clin Pathol 40(11):1282–1286PubMedPubMedCentralCrossRef Dundas SA, Kay R, Beck S, Cotton DW, Coup AJ, Slater DN, Underwood JC (1987) Can histopathologists reliably assess dysplasia in chronic inflammatory bowel disease? J Clin Pathol 40(11):1282–1286PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Melville DM, Jass JR, Morson BC, Pollock DJ, Richman PI, Shepherd NA, Ritchie JK, Love SB, Lennard-Jones JE (1989) Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum Pathol 20(10):1008–1014. doi:10.1016/0046-8177(89)90273-6 PubMedCrossRef Melville DM, Jass JR, Morson BC, Pollock DJ, Richman PI, Shepherd NA, Ritchie JK, Love SB, Lennard-Jones JE (1989) Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum Pathol 20(10):1008–1014. doi:10.​1016/​0046-8177(89)90273-6 PubMedCrossRef
33.
Zurück zum Zitat Hammarberg C, Slezak P, Tribukait B (1984) Early detection of malignancy in ulcerative colitis. A flow-cytometric DNA study. Cancer 53(2):291–295PubMedCrossRef Hammarberg C, Slezak P, Tribukait B (1984) Early detection of malignancy in ulcerative colitis. A flow-cytometric DNA study. Cancer 53(2):291–295PubMedCrossRef
34.
Zurück zum Zitat Burum-Auensen E, Deangelis PM, Schjolberg AR, Roislien J, Andersen SN, Clausen OP (2007) Spindle proteins aurora a and BUB1B, but not Mad2, are aberrantly expressed in dysplastic mucosa of patients with longstanding ulcerative colitis. J Clin Pathol 60(12):1403–1408 doi: jcp.2006.044305 [pii] 1136/jcp.2006.044305PubMedPubMedCentralCrossRef Burum-Auensen E, Deangelis PM, Schjolberg AR, Roislien J, Andersen SN, Clausen OP (2007) Spindle proteins aurora a and BUB1B, but not Mad2, are aberrantly expressed in dysplastic mucosa of patients with longstanding ulcerative colitis. J Clin Pathol 60(12):1403–1408 doi: jcp.2006.044305 [pii] 1136/jcp.2006.044305PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Sjoqvist U, Hertervig E, Nilsson A, Duan RD, Ost A, Tribukait B, Lofberg R (2002) Chronic colitis is associated with a reduction of mucosal alkaline sphingomyelinase activity. Inflamm Bowel Dis 8(4):258–263PubMedCrossRef Sjoqvist U, Hertervig E, Nilsson A, Duan RD, Ost A, Tribukait B, Lofberg R (2002) Chronic colitis is associated with a reduction of mucosal alkaline sphingomyelinase activity. Inflamm Bowel Dis 8(4):258–263PubMedCrossRef
36.
Zurück zum Zitat Keller R, Foerster EC, Kohler A, Floer B, Winde G, Terpe HJ, Domschke W (2001) Diagnostic value of DNA image cytometry in ulcerative colitis. Dig Dis Sci 46(4):870–878PubMedCrossRef Keller R, Foerster EC, Kohler A, Floer B, Winde G, Terpe HJ, Domschke W (2001) Diagnostic value of DNA image cytometry in ulcerative colitis. Dig Dis Sci 46(4):870–878PubMedCrossRef
37.
Zurück zum Zitat Burmer GC, Rabinovitch PS, Haggitt RC, Crispin DA, Brentnall TA, Kolli VR, Stevens AC, Rubin CE (1992) Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 103(5):1602–1610 doi:S0016508592004360 [pii]PubMedCrossRef Burmer GC, Rabinovitch PS, Haggitt RC, Crispin DA, Brentnall TA, Kolli VR, Stevens AC, Rubin CE (1992) Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 103(5):1602–1610 doi:S0016508592004360 [pii]PubMedCrossRef
38.
Zurück zum Zitat Lofberg R, Brostrom O, Karlen P, Ost A, Tribukait B (1992) DNA aneuploidy in ulcerative colitis: reproducibility, topographic distribution, and relation to dysplasia. Gastroenterology 102(4 Pt 1):1149–1154PubMedCrossRef Lofberg R, Brostrom O, Karlen P, Ost A, Tribukait B (1992) DNA aneuploidy in ulcerative colitis: reproducibility, topographic distribution, and relation to dysplasia. Gastroenterology 102(4 Pt 1):1149–1154PubMedCrossRef
39.
Zurück zum Zitat Porschen R, Molsberger G, Reis C, Borchard F, Reis HE, Eckardt VF, Purrmann J, Hengels KJ, Strohmeyer G (1992) DNA ploidy and dysplasia in ulcerative colitis—interim analysis of a prospective study. Zeitschrift Fur Gastroenterologie 30(12):857–862PubMed Porschen R, Molsberger G, Reis C, Borchard F, Reis HE, Eckardt VF, Purrmann J, Hengels KJ, Strohmeyer G (1992) DNA ploidy and dysplasia in ulcerative colitis—interim analysis of a prospective study. Zeitschrift Fur Gastroenterologie 30(12):857–862PubMed
40.
Zurück zum Zitat Levine DS, Rabinovitch PS, Haggitt RC, Blount PL, Dean PJ, Rubin CE, Reid BJ (1991) Distribution of aneuploid cell populations in ulcerative colitis with dysplasia or cancer. Gastroenterology 101(5):1198–1210 doi:S0016508591003712 [pii]PubMedCrossRef Levine DS, Rabinovitch PS, Haggitt RC, Blount PL, Dean PJ, Rubin CE, Reid BJ (1991) Distribution of aneuploid cell populations in ulcerative colitis with dysplasia or cancer. Gastroenterology 101(5):1198–1210 doi:S0016508591003712 [pii]PubMedCrossRef
41.
Zurück zum Zitat Meyer KF, Nause SL, Freitag-Wolf S, Kruger S, Bruch HP, Roblick UJ, Habermann JK (2013) Aneuploidy characterizes adjacent non-malignant mucosa of ulcerative colitis-associated but not sporadic colorectal carcinomas: a matched-pair analysis. Scand J Gastroenterol 48(6):679–687. doi:10.3109/00365521.2013.783103 PubMedCrossRef Meyer KF, Nause SL, Freitag-Wolf S, Kruger S, Bruch HP, Roblick UJ, Habermann JK (2013) Aneuploidy characterizes adjacent non-malignant mucosa of ulcerative colitis-associated but not sporadic colorectal carcinomas: a matched-pair analysis. Scand J Gastroenterol 48(6):679–687. doi:10.​3109/​00365521.​2013.​783103 PubMedCrossRef
42.
Zurück zum Zitat Grabsch H, Kerr D, Quirke P (2004) Is there a case for routine clinical application of ploidy measurements in gastrointestinal tumours? Histopathology 45(4):312–334 doi: HIS1901 [pii] 1111/j.1365-2559.2004.01901.xPubMedCrossRef Grabsch H, Kerr D, Quirke P (2004) Is there a case for routine clinical application of ploidy measurements in gastrointestinal tumours? Histopathology 45(4):312–334 doi: HIS1901 [pii] 1111/j.1365-2559.2004.01901.xPubMedCrossRef
44.
Zurück zum Zitat Holzmann K, Klump B, Borchard F, Gregor M, Porschen R (2001) Flow cytometric and histologic evaluation in a large cohort of patients with ulcerative colitis: correlation with clinical characteristics and impact on surveillance. Dis Colon rectum 44(10):1446–1455PubMedCrossRef Holzmann K, Klump B, Borchard F, Gregor M, Porschen R (2001) Flow cytometric and histologic evaluation in a large cohort of patients with ulcerative colitis: correlation with clinical characteristics and impact on surveillance. Dis Colon rectum 44(10):1446–1455PubMedCrossRef
45.
Zurück zum Zitat Sjoqvist U, Tribukait B, Ost A, Einarsson C, Oxelmark L, Lofberg R (2004) Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res 24(5B):3121–3127PubMed Sjoqvist U, Tribukait B, Ost A, Einarsson C, Oxelmark L, Lofberg R (2004) Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res 24(5B):3121–3127PubMed
46.
Zurück zum Zitat Habermann J, Lenander C, Roblick UJ, Kruger S, Ludwig D, Alaiya A, Freitag S, Dumbgen L, Bruch HP, Stange E, Salo S, Tryggvason K, Auer G, Schimmelpenning H (2001) Ulcerative colitis and colorectal carcinoma: DNA-profile, laminin-5 gamma2 chain and cyclin a expression as early markers for risk assessment. Scand J Gastroenterol 36(7):751–758PubMedCrossRef Habermann J, Lenander C, Roblick UJ, Kruger S, Ludwig D, Alaiya A, Freitag S, Dumbgen L, Bruch HP, Stange E, Salo S, Tryggvason K, Auer G, Schimmelpenning H (2001) Ulcerative colitis and colorectal carcinoma: DNA-profile, laminin-5 gamma2 chain and cyclin a expression as early markers for risk assessment. Scand J Gastroenterol 36(7):751–758PubMedCrossRef
48.
Zurück zum Zitat Karlen P, Young E, Brostrom O, Lofberg R, Tribukait B, Ost K, Bodian C, Itzkowitz S (1998) Sialyl-Tn antigen as a marker of colon cancer risk in ulcerative colitis: relation to dysplasia and DNA aneuploidy. Gastroenterology 115(6):1395–1404 doi:S0016508598006015 [pii]PubMedCrossRef Karlen P, Young E, Brostrom O, Lofberg R, Tribukait B, Ost K, Bodian C, Itzkowitz S (1998) Sialyl-Tn antigen as a marker of colon cancer risk in ulcerative colitis: relation to dysplasia and DNA aneuploidy. Gastroenterology 115(6):1395–1404 doi:S0016508598006015 [pii]PubMedCrossRef
49.
Zurück zum Zitat Befrits R, Hammarberg C, Rubio C, Jaramillo E, Tribukait B (1994) DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. Dis Colon rectum 37(4):313–319 discussion 319-320PubMedCrossRef Befrits R, Hammarberg C, Rubio C, Jaramillo E, Tribukait B (1994) DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. Dis Colon rectum 37(4):313–319 discussion 319-320PubMedCrossRef
50.
Zurück zum Zitat Rutegard J, Ahsgren L, Stenling R, Roos G (1989) DNA content and mucosal dysplasia in ulcerative colitis. Flow cytometric analysis in patients with dysplastic or indefinite morphologic changes in the colorectal mucosa. Dis Colon rectum 32(12):1055–1059PubMedCrossRef Rutegard J, Ahsgren L, Stenling R, Roos G (1989) DNA content and mucosal dysplasia in ulcerative colitis. Flow cytometric analysis in patients with dysplastic or indefinite morphologic changes in the colorectal mucosa. Dis Colon rectum 32(12):1055–1059PubMedCrossRef
51.
Zurück zum Zitat Rutegard J, Ahsgren L, Stenling R, Roos G (1988) DNA content in ulcerative colitis. Flow cytometric analysis in a patient series from a defined area. Dis Colon rectum 31(9):710–715PubMedCrossRef Rutegard J, Ahsgren L, Stenling R, Roos G (1988) DNA content in ulcerative colitis. Flow cytometric analysis in a patient series from a defined area. Dis Colon rectum 31(9):710–715PubMedCrossRef
52.
Zurück zum Zitat Lofberg R, Tribukait B, Ost A, Brostrom O, Reichard H (1987) Flow cytometric DNA analysis in longstanding ulcerative colitis: a method of prediction of dysplasia and carcinoma development? Gut 28(9):1100–1106PubMedPubMedCentralCrossRef Lofberg R, Tribukait B, Ost A, Brostrom O, Reichard H (1987) Flow cytometric DNA analysis in longstanding ulcerative colitis: a method of prediction of dysplasia and carcinoma development? Gut 28(9):1100–1106PubMedPubMedCentralCrossRef
53.
54.
Zurück zum Zitat Auer G, Ono J, Nasiell M, Caspersson T, Kato H, Konaka C, Hayata Y (1982) Reversibility of bronchial cell atypia. Cancer Res 42(10):4241–4247PubMed Auer G, Ono J, Nasiell M, Caspersson T, Kato H, Konaka C, Hayata Y (1982) Reversibility of bronchial cell atypia. Cancer Res 42(10):4241–4247PubMed
55.
Zurück zum Zitat Ono J, Auer G, Caspersson T, Nasiell M, Saito T, Konaka C, Kato H, Hayata Y (1984) Reversibility of 20-methylcholanthrene-induced bronchial cell atypia in dogs. Cancer 54(6):1030–1037PubMedCrossRef Ono J, Auer G, Caspersson T, Nasiell M, Saito T, Konaka C, Kato H, Hayata Y (1984) Reversibility of 20-methylcholanthrene-induced bronchial cell atypia in dogs. Cancer 54(6):1030–1037PubMedCrossRef
56.
Zurück zum Zitat Lanigan D, McLean PA, Curran B, Leader M (1993) Comparison of flow and static image cytometry in the determination of ploidy. J Clin Pathol 46(2):135–139PubMedPubMedCentralCrossRef Lanigan D, McLean PA, Curran B, Leader M (1993) Comparison of flow and static image cytometry in the determination of ploidy. J Clin Pathol 46(2):135–139PubMedPubMedCentralCrossRef
57.
Zurück zum Zitat Bauer TW, Tubbs RR, Edinger MG, Suit PF, Gephardt GN, Levin HS (1990) A prospective comparison of DNA quantitation by image and flow cytometry. Am J Clin Pathol 93(3):322–326PubMedCrossRef Bauer TW, Tubbs RR, Edinger MG, Suit PF, Gephardt GN, Levin HS (1990) A prospective comparison of DNA quantitation by image and flow cytometry. Am J Clin Pathol 93(3):322–326PubMedCrossRef
58.
Zurück zum Zitat Willenbucher RF, Aust DE, Chang CG, Zelman SJ, Ferrell LD, Moore DH 2nd, Waldman FM (1999) Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol 154(6):1825–1830 doi: 1016/S0002-9440(10)65438-7 S0002-9440(10)65438-7 [pii]PubMedPubMedCentralCrossRef Willenbucher RF, Aust DE, Chang CG, Zelman SJ, Ferrell LD, Moore DH 2nd, Waldman FM (1999) Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol 154(6):1825–1830 doi: 1016/S0002-9440(10)65438-7 S0002-9440(10)65438-7 [pii]PubMedPubMedCentralCrossRef
Metadaten
Titel
Combining aneuploidy and dysplasia for colitis’ cancer risk assessment outperforms current surveillance efficiency: a meta-analysis
verfasst von
Rüdiger Meyer
Sandra Freitag-Wolf
Silke Blindow
Jürgen Büning
Jens K. Habermann
Publikationsdatum
20.10.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 2/2017
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-016-2684-5

Weitere Artikel der Ausgabe 2/2017

International Journal of Colorectal Disease 2/2017 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.